Evidence map›Paper›PMID 38414939›Full record

ArticleEcancermedicalscience2023

Localised breast cancer: neoadjuvant chemotherapy impact evaluation on the pathological complete response (PCR) in a lower middle-income country.

Ganiou Adjadé, Hassan Abdelilah Tafenzi, Houda Jouihri, Nadin Shawar Al Tamimi, Yousra Bennouna, Gustave Négamiyimana, Kalil Cisse, Ismail Essadi, Mohammed El Fadli, Rhizlane Belbaraka

Abstract read
In one paragraph

Article in Ecancermedicalscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ganiou AdjadéDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Hassan Abdelilah TafenziDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Houda JouihriDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Nadin Shawar Al TamimiDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Yousra BennounaDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Gustave NégamiyimanaDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Kalil CisseDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Ismail EssadiBiosciences and Laboratory, Faculty of Medicine and Pharmacy, Cady Ayyad University, 7010, Sidi Abbad, Marrakech 40000, Morocco.
Mohammed El FadliDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Rhizlane BelbarakaDepartment of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Neoadjuvant chemotherapy followed by surgery remains the current recommended therapeutic strategy for the management of locally advanced breast cancer. The standard chemotherapy protocol is sequential with anthracycline followed by taxanes. However public hospitals in Morocco are confronted with a shortage in healthcare products. We, therefore, evaluated the efficacy of the different protocols proposed to patients, by evaluating the clinical response after chemotherapy especially through the pathological complete response (PCR) after surgery. Methods: We focused on the database of the medical oncology department of the only public hospital covering middle and southern Morocco. We included patients diagnosed between 2018 and 2020. Two groups of patients distinguished in group A (GA) received the standard therapy, and group B (GB) received a non-standard protocol. The therapeutic response was assessed clinically before surgery and then by pathological examination of the surgical specimens. The Sataloff classification defined the histological response for both tumour and lymph nodes. We included both groups in one variable to determine their impact on outcomes. A logistic regression-based analysis was adopted to define variables related to the PCR. Results: Over the study period, 120 patients met our inclusion criteria. They were distinguished at 72% in GA and 28% in GB. 60.8% over 120 got a partial response, whereas, only 33.3% achieved a complete response. The general PCR rate was 28% with 14.3% in GB and 85.7% in GA. The tumour PCR was obtained in 40 (33.3%) over 120 patients and 51.7% of lymph node PCR. The multivariate logistic regression analysis results show no relative factors associated with general PCR achievement. Conclusion: These first interesting results from an institutional database inform us about our clinical practice and require additional research using prospective randomised controlled studies.

Indexed as

breast cancerchemotherapylocalisedMorocconeoadjuvantPCR

Identifiers

PMID38414939
PMCPMC10898881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.